Atezolizumab: This anti-cancer drug is an effector-less (FcγR-binding deficient) humanised immunoglobulin G1 monoclonal antibody that targets PD-L1 and blocks its interaction with PD-1 and B7.1 [116]. This evidence concerns the gene CD274 and cancer.